Access free, up-to-date clinical references for managing parapneumonic effusions and empyema in pneumonia. Our content provides valuable insights for physicians.

EFFUSION into the general pleural cavity is a frequent manifestation of congestive heart failure. On the other hand, pleural effusion localized in an interlobar space is not a common finding, since ...

Rapidly recurrent malignant pleural effusions are not uncommon in patients with carcinoma of the breast, lung, uterus and so forth. The associated severe dyspnea is often the most distressing symptom.

Lung Therapeutics is developing two primary drugs: LTI-01 to treat loculated pleural effusion, a serious complication of pneumonia, and LTI-03 to treat idiopathic pulmonary fibrosis.

Loculated pleural effusion (LPE) is a condition in which fluid is trapped within the pleural cavity due to fibrinous adhesions, leading to pain, shortness of breath and possibly sepsis.

It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.

The company’s lead drug, LTI-01, is in development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients.

Rein Therapeutics is also working on other products, including LTI-01 for loculated pleural effusions and LTI-05 for cystic fibrosis. These products are noted to have the potential to contribute ...

LTI-01 is in development for loculated pleural effusion ("LPE"), a serious consequence of pneumonia with significant unmet medical need. La historia continúa ...

Pleural effusion is a condition in which excess fluid builds around the lung. Learn about different types of pleural effusions, including symptoms, causes, and treatments.

Lung Therapeutics announced that it received Orphan Drug Designation for LTI-01, an injectable designed for the treatment of loculated pleural effusion.